UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 5, 2013
ACELRX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| DELAWARE | 001-35068 | 41-2193603 | ||
| (State of incorporation) | (Commission File No.) |
(IRS Employer Identification No.) |
351 Galveston Drive
Redwood City, CA 94063
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (650) 216-3500
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
2013 Base Salaries
On February 5, 2013, the Board of Directors (the “Board”) of AcelRx Pharmaceuticals, Inc. (the “Company”) approved the 2013 base salaries (effective retroactively to January 1, 2013) for certain of the Company’s named executive officers (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission, the “NEOs”) in the amounts set forth in the table below.
| Named Executive Officer | 2013 Base Salary | |||
| Richard A. King, Chief Executive Officer |
$ | 475,000 | ||
| James H. Welch, Chief Financial Officer |
$ | 307,500 | ||
| Pamela P. Palmer, M.D., Ph.D., Chief Medical Officer |
$ | 409,000 | ||
| Badri Dasu, Chief Engineering Officer |
$ | 301,500 | ||
| Lawrence G. Hamel, Chief Development Officer |
$ | 301,000 | ||
Bonus Payments
On February 5, 2013, the Board approved bonus payments for 2012 performance for certain of the NEOs in the amount set forth in the table below, in accordance with the Company’s established 2012 Cash Bonus Plan.
| Named Executive Officer | 2012 Bonus | |||
| Richard A. King, Chief Executive Officer |
$ | 170,400 | ||
| James H. Welch, Chief Financial Officer |
$ | 95,232 | ||
| Pamela P. Palmer, M.D., Ph.D., Chief Medical Officer |
$ | 134,034 | ||
| Badri Dasu, Chief Engineering Officer |
$ | 95,160 | ||
| Lawrence G. Hamel, Chief Development Officer |
$ | 93,964 | ||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: February 11, 2013 | ACELRX PHARMACEUTICALS, INC. | |||||
| By: | /s/ James H. Welch | |||||
| James H. Welch | ||||||
| Chief Financial Officer | ||||||